15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $134M | $4973 | 62.9% | 5.4% | $10M | $11M | $17M |
| 2024 | $117M | -$16449 | 58.2% | -10.3% | -$16M | $22M | $6M |
| 2023 | $91M | $660 | 60.8% | -11.1% | -$11M | $17M | $6M |
| 2022 | $58M | -$8M | 55.4% | -11.7% | -$7M | $10M | $20M |
| 2021 | $55M | -$5M | 58.8% | -7.0% | -$2M | $12M | $18M |
| 2020 | $53M | -$7M | 64.5% | -1.4% | -$2M | — | $2M |
| 2019 | $65M | -$8M | 65.7% | -3.5% | -$1M | $76M | $5M |
| 2018 | $72M | -$70M | 60.2% | -83.2% | $588000 | $78M | $7M |
| 2017 | — | -$52M | — | — | — | $138M | $3M |
| 2016 | — | -$19M | — | — | — | $119M | $3M |
| 2015 | — | -$2M | — | — | — | $111M | $6M |
| 2014 | — | -$11M | — | — | — | $21M | $4M |
| 2013 | — | -$13M | — | — | — | $16M | $3M |
| 2012 | — | -$8M | — | — | -$13M | $15M | $5M |
| 2011 | — | -$3M | — | — | -$8M | $8M | $751111 |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $21M | -$3M | 57.3% | -14.0% | -$2M | $8M | $12M |
| Dec '25 | $32M | $57000 | 54.9% | -2.9% | $5M | $11M | $17M |
| Sep '25 | $33M | $1M | 66.1% | 7.6% | $4M | $17M | $10M |
| Jun '25 | $35M | $4M | 68.6% | 13.1% | $910000 | $22M | $7M |
| Mar '25 | $33M | $58000 | 61.5% | 3.2% | $87000 | $22M | $5M |
| Dec '24 | $32M | -$3M | 50.8% | -6.0% | -$7000 | $22M | $6M |
| Sep '24 | $28M | -$5M | 58.4% | -13.5% | -$4M | $19M | $7M |
| Jun '24 | $30M | -$4M | 62.1% | -9.8% | -$6M | $22M | $5M |
| Mar '24 | $28M | -$4M | 62.1% | -12.4% | -$7M | $17M | $5M |
| Dec '23 | $28M | -$4M | 61.0% | -13.5% | -$1M | $17M | $6M |
| Sep '23 | $25M | $9M | 61.3% | -13.5% | -$4M | $14M | $9M |
| Jun '23 | $20M | -$2M | 61.6% | -6.9% | -$3M | $16M | $4M |
| Mar '23 | $18M | -$2M | 58.7% | -8.8% | -$3M | $12M | $5M |
| Dec '22 | $15M | -$2M | 54.4% | -11.3% | -$3M | $10M | $20M |
| Sep '22 | $14M | -$2M | 54.6% | -13.1% | -$3M | $11M | $17M |
| Jun '22 | $15M | -$2M | 54.8% | -8.5% | -$311000 | $12M | $16M |
| Mar '22 | $13M | -$2M | 58.3% | -14.1% | -$1M | $12M | $17M |
| Dec '21 | $14M | -$2M | 55.1% | -13.7% | -$203000 | $12M | $18M |
| Sep '21 | $14M | -$2M | 52.2% | -10.5% | -$1M | $12M | $18M |
| Jun '21 | $15M | -$733000 | 63.5% | -3.3% | $2M | $12M | $20M |
How the market has priced XTNT against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Xtant Medical Holdings, Inc.'s revenue has grown 20.2% per year. These are computed facts, not advice.
As of FY2025, Xtant Medical Holdings, Inc. reported $11M of total debt against $17M of cash; operating income covered interest expense 2.0×.
In FY2025, gross margin was 62.9%, operating margin 5.4%, and net margin 0.0%.
As of Jun '26, Xtant Medical Holdings, Inc. traded at a price-to-earnings ratio of about 12136.6× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.